These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 17183261)
1. Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade. Del Vecchio L; Procaccio M; Viganò S; Cusi D Nat Clin Pract Nephrol; 2007 Jan; 3(1):42-9. PubMed ID: 17183261 [TBL] [Abstract][Full Text] [Related]
2. [Aldosterone and kidney damage: clinical implications]. Del Vecchio L; Sitia S G Ital Nefrol; 2009; 26(3):347-54. PubMed ID: 19554532 [TBL] [Abstract][Full Text] [Related]
3. Aldosterone and progression of kidney disease. Cortinovis M; Perico N; Cattaneo D; Remuzzi G Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):133-43. PubMed ID: 19171691 [TBL] [Abstract][Full Text] [Related]
4. [Aldosterone blockade in essential hypertension]. Venco A; Grandi AM Ital Heart J; 2005 May; 6 Suppl 1():34S-42S. PubMed ID: 15945298 [TBL] [Abstract][Full Text] [Related]
5. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019 [TBL] [Abstract][Full Text] [Related]
6. Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial? Coca SG; Perazella MA Expert Rev Cardiovasc Ther; 2005 May; 3(3):497-512. PubMed ID: 15889977 [TBL] [Abstract][Full Text] [Related]
7. The aggravating mechanisms of aldosterone on kidney fibrosis. Remuzzi G; Cattaneo D; Perico N J Am Soc Nephrol; 2008 Aug; 19(8):1459-62. PubMed ID: 18550649 [TBL] [Abstract][Full Text] [Related]
8. Neurohormones and heart failure: the importance of aldosterone. Odedra K; Ferro A Int J Clin Pract; 2006 Jul; 60(7):835-46. PubMed ID: 16846401 [TBL] [Abstract][Full Text] [Related]
13. Effect of spironolactone on C-reactive protein levels in patients with heart disease. Godfrey V; Farquharson CA; Macdonald JE; Yee KM; Struthers AD Int J Cardiol; 2007 Apr; 117(2):282-4. PubMed ID: 16899309 [TBL] [Abstract][Full Text] [Related]
14. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Makkar KM; Sanoski CA; Spinler SA Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Cohn JN; Colucci W Am J Cardiol; 2006 May; 97(10A):4F-12F. PubMed ID: 16698330 [TBL] [Abstract][Full Text] [Related]
18. Aldosterone and cardiovascular pathology: from bench to bedside. Vintilă M; Băluţă M Rom J Intern Med; 2004; 42(1):15-26. PubMed ID: 15529592 [TBL] [Abstract][Full Text] [Related]
19. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need? Lim S Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878 [TBL] [Abstract][Full Text] [Related]
20. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. Shah NC; Pringle SD; Donnan PT; Struthers AD J Hypertens; 2007 Nov; 25(11):2345-51. PubMed ID: 17921831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]